# Biotech M&A Target Screening Pipeline — Technical Review & Architecture Summary

**Reviewed Document:** Biotech M&A Target Screening Pipeline — Technical Specification (v0.6)  
**Target Domain:** US-Listed Clinical-Stage Biotechnology (Event-Driven M&A Strategy)  
**Overall Evaluation:** Exemplary / Production-Grade  

---

## 1. Executive Summary

The specification presents a robust, point-in-time-correct data architecture designed to rank US biotechnology companies by acquisition probability ($P(\text{deal})$) and expected financial return ($E[\text{return}]$).

Unlike generic quantitative screening frameworks, this pipeline addresses the specific structural mechanics of the pharmaceutical industry:
* **The Revenue Cliff:** Matching acquirer patent expirations (via FDA Orange/Purple Books) with target clinical pipelines.
* **Survivorship Bias Elimination:** Constructing historical rosters directly from SEC EDGAR DERA datasets rather than survivorship-biased commercial price vendors.
* **Bitemporal Data Integrity:** Enforcing strict separation of `valid_from` and `known_from` timestamps to prevent lookahead leaks in backtests.
* **Separation of Valuation & Likelihood:** Disentangling probability of a bid from post-announcement upside ($P(\text{deal})$ vs. $E[\text{return} \mid \text{deal}]$).

---

## 2. Key Architecture Strengths

### 2.1 Unadjusted Price & Corporate Action Storage (§2.0.7)
Storing raw OHLCV alongside a point-in-time corporate actions table (adjusting dynamically at query time) prevents:
* **Market-Cap Corruption:** Multiplying retro-adjusted historical prices by unadjusted as-filed share counts.
* **Level-Lookahead Contamination:** Filtering historical penny-stock regimes using post-split price levels.

### 2.2 Dual-Target Structural Formulation (§5.3)
Ranking purely on $P(\text{deal})$ introduces a adverse selection hazard: distressed firms with failing assets or dwindling cash runway often sell at steep discounts or as cash shells, generating positive deal labels with negative investment returns. The explicit separation into a two-target model ($P(\text{deal})$ and $E[\text{return} \mid \text{deal}]$) ensures actionable equity signals.

### 2.3 Pairwise Feasibility Gating (§4.4)
Treating regulatory friction (CFIUS/foreign investment screening) and FTC antitrust overlap as multiplicative gates inside the pairwise `fit(acquirer, target)` function—rather than flat additive penalties at the target level—is domain-accurate. A target facing heavy FTC scrutiny with Acquirer A remains fully viable for Acquirer B.

---

## 3. Recommended Enhancements & Pipeline Improvements

While v0.6 is production-ready, incorporating the following optimizations will enhance signal fidelity, lower operational drag, and prevent trading execution bottlenecks.

```
┌─────────────────────────────────────────────────────────────────────────┐
│                      PROPOSED PIPELINE ENHANCEMENTS                     │
├──────────────────────────┬──────────────────────┬───────────────────────┤
│    DATA INGESTION &      │   MODELING & FIT     │     MICROSTRUCTURE    │
│    NLP ENRICHMENT        │   REFINEMENT         │     & RISK GATING     │
├──────────────────────────┼──────────────────────┼───────────────────────┤
│ • Automated 10-K/EX-10   │ • Phase-Conditional  │ • Liquidity & Spread  │
│   Extraction (LLM/SLM)   │   Orphan Modifiers   │   Filters (ADV/AMI)   │
│ • FDA Regulatory Path    │ • Competitive Crowd- │ • Cross-Trial Cash    │
│   Tracking (SPA, RMAT)   │   ing Metrics (TA)   │   Burn Modeling       │
└──────────────────────────┴──────────────────────┴───────────────────────┘
```

### 3.1 Market Microstructure & Liquidity Filters (Block C Addendum)
* **Problem:** Microcap biotechs ($25M–$150M market cap) often exhibit severely impaired daily liquidity ($50K–$100K ADV) and wide bid-ask spreads.
* **Improvement:** Add explicit market microstructure gates to Block C:
  * **Average Daily Volume (30d / 90d ADV):** Reject or heavily flag targets where a standard 1% portfolio allocation exceeds 10–15% of 10-day cumulative volume.
  * **Amihud Illiquidity Metric:** Quantify price impact per dollar traded to ensure actionable entries.

### 3.2 Automated NLP Pipeline for Block G & EX-10 (LLM/SLM Integration)
* **Problem:** Manual review of Schedule 13D Item 4 intents, 8-K strategic review disclosures, and EX-10 agreement exhibits (§2.6.3) creates a human bottleneck in the review queue (§3.4).
* **Improvement:** Implement a zero-shot or fine-tuned Small Language Model (SLM, e.g., Llama-3-8B / Mistral) parser as a **candidate generator**:
  * Extract structured JSON schemas (Counterparty, Option Triggers, Royalty Rights, Termination Fees) from raw 8-K/EX-10 text.
  * Human reviewers in §3.4 transition from *manual extraction* to *one-click verification*, reducing queue latency from 1 business day to minutes.

### 3.3 Enhanced Regulatory Pathway Signals (Block B Addendum)
* **Problem:** Base-rate probability of approval ($PoA$) in §4.2 treats all Phase II/III trials within a therapeutic area similarly, ignoring accelerated regulatory designations.
* **Improvement:** Incorporate FDA designation features into `lead_asset_poa`:
  * **Special Protocol Assessment (SPA):** Agreement with FDA on trial design significantly reduces regulatory risk.
  * **Breakthrough Therapy / RMAT / Fast Track Designations:** Multiplicative boosts to transition probabilities.
  * **Advisory Committee (AdCom) Scheduling:** Track AdCom voting dates as high-precision catalyst events.

### 3.4 Competitive Crowd-In Index (Block D Addendum)
* **Problem:** Multiple targets developing drugs for the exact same target protein (e.g., TIGIT, Claudin 18.2, GLP-1/GIP) diminish individual target value once a peer in that cohort is acquired.
* **Improvement:** Add a `competitive_density` index per asset class:
  * Track the number of active industry programs targeting the same mechanism of action (MoA).
  * High density increases overall $P(\text{deal})$ for the sector leader, but introduces a sharp penalty for late-stage followers after the first deal in the category closes.

---

## 4. Summary of Verification Milestones

| Milestone | Critical Path Verification Focus |
|---|---|
| **M1–M3** | Validate bitemporal lookahead audit with stratified sampling (§8.3) covering vendor price updates and 13D/13F filings. |
| **M4–M5** | Ensure Tier promotions (§5.2) correctly segregate public process signals from unannounced fundamental value. |
| **M6** | Audit label dataset to confirm complete exclusion of reverse mergers, liquidations, and cash-shell transactions. |

---

## 5. Conclusion

The specification provides an exceptionally solid, quantitative foundation for event-driven biotech investing. It avoids common survivorship and lookahead traps that ruin quant models in this sector. Implementing the suggested liquidity gates and LLM-assisted queue parser will elevate this pipeline into a best-in-class institutional platform.
```

### Резюме изменений и ключевых идей в файле:
1. **Оценка документа:** Дана высокая институциональная оценка технической точности спецификации (учет сплитов, упреждения данных, битемпоральность).
2. **Предложенные улучшения (Improvements):**
   * **Микроструктура рынка (Microstructure):** Добавление фильтров ликвидности (Amihud Illiquidity, ADV) для защиты от проскальзывания в микрокапах.
   * **LLM-автоматизация:** Использование небольших языковых моделей (SLM/LLM) для первичного структурирования сложных текстов контрактов (EX-10) и 13D, чтобы ускорить ручную очередь проверки до нескольких минут.
   * **Регуляторные сигналы FDA:** Учет специальных статусов FDA (SPA, Breakthrough, Fast Track, AdCom), повышающих вероятность одобрения.
   * **Конкурентная плотность (MoA Density):** Оценка количества стартапов, разрабатывающих препараты против одной и той же мишени (например, GLP-1), с понижением оценки фолловеров после первой сделки в секторе.